Events down, disability-free survival unchanged
View original
Kausik RayChair in Public Health, Imperial College London
STAREE fills a data gap: statins in the elderly
View original ↗A non-pharma, 10,000-patient answer that includes the elderly, especially women
View originals
30 percent fewer major events in over-70s with no prior cardiovascular disease
View original
Read the result as protection from cardiovascular events in older people without prior ASCVD.
View original
Watching for the dementia data as a separate endpoint; the combined death, dementia, or disability endpoint was not significant.
View original
At last, robust randomized evidence on statins for primary prevention in older adults.
View original
Long-awaited evidence of benefit for statins in primary prevention at 70 and older.
View original
Walked through the design: 9,971 Australians 70 and older, atorvastatin 40 mg versus placebo, median 5.9 years.
View original
Lower MACE risk with atorvastatin, no gain in disability-free survival.
View original
CR
Chris Reid
Context·Professor, Curtin University. STAREE collaborator
The trial aims to give GPs confidence to prescribe statins when needed, while ensuring benefits exceed the risks.
View original ↗ZZ
Zhen ZhouContext·Research fellow, University of Tasmania
Called STAREE the largest primary prevention statin trial in the elderly, built to show whether daily statins help healthy older adults live longer and healthier.
Reported the session live: the lineup, the trial setup, and the simultaneous NEJM publication.
View original
Yury MareevContext·National Research Center for Preventive Medicine
Listed STAREE among his main trials to watch at ESC 2026.
View original
Opened the thread before the results with a background summary of the trial.
View original